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ABSTRACT

Recent research suggests that the development of behavioral sensitization to
cocaine may be mediated by the repeated stimulation of either DI-type or D2-type
dopamine receptors. The purpose of the present study was to test this hypothesis by
determining whether concurrent treatments with a DI-type dopamine antagonist (SCH
23390) and a D2-type dopamine antagonist (eticlopride) combined would prevent the
development ofbehavioral sensitization to cocaine.

Forty-eight male Wistar rats, that weighed between 200 and 250g were
injected daily for four days with one of the following drug combinations:
vehicle/vehicle, vehicle/cocaine (ISmg/kg), SCH 23390 (O. lmg/kg)/eticlopride

(O. lmg/kg)/vehicle, or SCH 23390/eticlopride/cocaine. Each rat was first injected
S.C. with either a combination of SCH 23390 and eticlopride or vehicle, and then 25
min later, each rat was injected I.P. with either cocaine or vehicle. Five min after the
second injection, each rat was tested for locomotor activity in photocell activity boxes
(Med-Associates) for 60 min. On day five, all rats were tested for activity after a
challenge injection of cocaine (10 mg/kg) alone.
The major findings were as follows: a) rats treated with cocaine alone were
significantly more active during the pretreatment phase than rats treated with only
vehicle; b) combined SCH 23390/eticlopride treatments produced a significant
suppression of activity on all test days, and completely blocked the acute activating
effects of cocaine; c) rats pretreated with cocaine displayed a greater activity response
to the challenge injection of cocaine on day five than did rats pretreated with only
vehicle (i.e., sensitization); d) concurrent pretreatment with the antagonist
combination did not block the development of behavioral sensitization to cocaine; and
e) pretreatment with the antagonist combination alone increased subsequent sensitivity
to cocaine.
Consistent with previous research, repeated cocaine treatments resulted in the
development of behavioral sensitization. Although the antagonist combination

completely blocked the acute locomotor-activating effects of cocaine, pretreatment
with the antagonist combination did not block the development of behavioral
sensitization to cocaine. These findings suggest that the repeated stimulation of
dopamine receptors is not necessary for the development of cocaine-induced
behavioral sensitization.
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CHAPTER I
INTRODUCTION

I. PsychostimulantDrugs and Behavioral Sensitization:
Drugs of abuse have become a increasing concern in our society. One category of
drugs that receives a great deal of attention is that ofpsychostimulants. Today,
stimulant drugs such as amphetamine and cocaine remain among the most widely
abused of the many psychoactive compounds available (Robinson & Becker, 1986,
Kalivas & Stewart, 1991; Stewart & Baldiani, 1993). When taken acutely,
psychostimulants induce euphoria and heightened arousal, but after chronic use a
variety of behavioral disorders may develop. Initially, psychostimulant abuse may
result in craving, and a supersensitivity to other psychostimulants. With repeated selfadministration, a pattern of compulsive drug-seeking and drug-taking behavior often
occurs (Robinson & Berridge, 1993; Robinson & Becker, 1986; Berridge & Robinson,
1995). In addition, when repeatedly, or chronically administered, various behavioral
disorders may result. Such disorders include panic attacks, delirium, and
schizophrenic-like psychoses (Robinson & Becker, 1986, Robinson & Berridge,1993;
Kalivas & Stewart, 1991). Although these disorders may subside if drug use is
discontinued, they have been shown to resurface as many as ten years later if drug use
is reinstated (Kalivas et al,1991; Ellinwood, 1967; Kramer, Fischman, & Littlefield,
1967). Thus, it is apparent that after chronic use of psychomotor stimulants,
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long lasting alterations in the central nervous system occur (Mattingly, Gotsick &
Salmanca, 1988).
Repeated psychomotor stimulant treatment in animals produces behavioral
sensiti_zation (Kalivas & Stewart, 1991; Robinson & Becker, 1986; Segal, 1975).
Behavioral sensitization is said to occur when the same dose of a drug, repeatedly
administered, produces a progressively greater behavioral effect. Once established,
this behavioral supersensitivity is persistent for weeks or even months (Browne &
Segal, 1977; Peris & Zahniser, 1987). For example, when rats are initially injected
with cocaine, a modest increase in locomotor activity is usually elicited. After
repeated treatments, however, the same dose of cocaine produces a significantly
greater hyperactivity response (Angrist, 1983; Mattingly, Hart, Lim, & Perkins, 1994;
Segal & Schuckit, 1983). In addition, recent evidence suggests that the rewarding
effects of psychostimulant drugs may also become sensitized with repeated drug
administrations (Lett 1989; Pierre & Vezina, 1997).
Neurobiological changes that mediate behavioral sensitization in rats are widely
thought to be the same as those that produce the behavioral disorders associated with
psychostimulant abuse in humans (Kalivas & Stewart, 1991; Robinson & Becker,
1986). In addition, these neurobiological changes may also be responsible for the
intense craving and compulsive drug-seeking behavior that develops in humans after
chronic psychostimulant abuse (Robinson & Berridge, I 993). Consequently, current
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research is seeking to determine the neurobiological mechanisms which mediate the
development and persistence of behavioral sensitization.

II. Dopamine Receptors and Dopamine Mediation of Behavioral Sensitization:
The rewarding and activating effects of psychostimulant drugs appear to be
mediated by the dopaminergic neurotransmitter system (Wise & Bozarth, 1985; Wise
& Bozarth, 1987). Psychostimulant drugs act to block the re-uptake and /or promote
the release of dopamine into the synaptic cleft, and this action in forebrain dopamine
terminal fields is thought to mediate much of the acute locomotor stimulant effect of
these drugs (Kalivas & Stewart, 1991). The dopamine neurons of primary interest in
the study of behavioral sensitization are located in the ventral tegmentum of the
mesencephalon and were originally categorized as the A9 and Al O cell clusters. The
Al O region is localized predominantly to the ventral tegmental area, and projects to
the structures closely associated with the limbic system, most prominently the
ventromedial portion of the striatal complex referred to as the nucleus accumbens, but
also the olfactory tubercle, septa! nucleus, and other limbic related areas (White,
1996). This system is considered separate from the nigrostriatal dopamine system in
which the dopamine cell bodies in the A9 region are localized almost exclusively to the
substantia nigra pars compacta, which projects to the neostriatum (Kalivas & Stewart,
1991).
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The acute motor stimulant effects of psychostimulant drugs such as
amphetamine and cocaine are believed to result from activation of the mesolimbic
dopamine system which arises from Al O dopamine neurons to innervate the nucleus
accumbens and other limbic brain structures (Steketee, Striplin, Murray, & Kalivas
1990). Despite the overlapping anatomy of the nigrostriatal and mesolimbic dopamine
systems, each system appears to subserve distinct aspects of behavior. Current
research has indicated that the nigrostriatal dopamine system facilitates motor
preparatory processes and also stereotypic behaviors in rats. In contrast, the
mesolimbic dopamine system facilitates the impact of stimulus-reward associations on
behavior involved in incentive motivational processes, drug abuse, and craving
(Robinson & Berridge, 1993; White 1996).
Recent advances in molecular biology have revealed multiple dopamine
receptor subtypes (Civelli, Bunzow, & Grandy, 1993; Gingrich & Caron, 1993).
Researchers have now distinguished five distinct subtypes of dopamine receptors.
These five subtypes, however, can be divided into two families based upon molecular,
biochemical, and pharmacological properties. The D 1 and DS receptor subtypes are
alike in that they are found post-synaptically and stimulate adenlate cyclase enzyme
activity. The D2 subfamily includes the D2, D3, and D4 receptor subtypes. The D2,
D3, and D4 subtypes are similar in that they are located both pre- and postsynaptically and are either unlinked or inhibit the adenlate cyclase enzyme (Schwartz,
Giros, Martres, & Sokoloff, 1992). Due to the similarities of these receptor subtypes,
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DI or D2 will refer to DI-type or D2-type receptors rather than specific DI or D2
receptor subtypes. Currently, a number of drugs are available that are relatively
selective to either the DI-type or the D2-type receptor families. However, few drugs
are available that are sufficiently selective for individual receptors within either family.
Over the past decade, many researchers have focused their attention on
discovering how different dopamine receptor types are involved in mediating the
development of behavioral sensitization to psychostimulant drugs. Conceptualizing
the role of various receptor sub-types may be important to the development of
psychotherapeutic drugs with fewer side effects. In addition, an understanding of the
involvement of these receptors in the development of behavioral sensitization may
allow more effective methods of treating drug abuse to be developed.

III. Dopamine Antagonists and Behavioral Sensitization to Apomorphine and
Amphetamine:
Most drugs that induce behavioral sensitization, either directly ( e.g.
apomorphine) or indirectly (e.g. cocaine, amphetamine) result in an increased
stimulation of both dopamine D1 and D2 receptor subtypes. One approach to study
the involvement ofindividual receptor subtypes in the development of sensitization has
been to administer a drug that selectively blocks or antagonizes a particular receptor
concurrently with a psychostimulant drug. Most of the research using this strategy
suggests that repeated stimulation ofD I receptors is critical to the development of
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sensitization. For example, the development of behavioral sensitization to
amphetamine is prevented by the co-administration of the selective D 1 antagonist,
SCH-23390 (Stewart & Vezina, 1989). In contrast, co-administration of D2
dopamine receptor antagonists (e.g. sulpiride, pimozide, metoclopromide, or RO-2225 86) does not block behavioral sensitization to amphetamine (Drew & Glick, 1990;
Stewart & Vezina, 1989; Vezina & Stewart, 1989). Similarly, the development of
behavioral sensitization to the direct D l/D2 agonist apomorphine is also prevented by
the co-administration of dopamine D 1, but not D2 receptor antagonists (Mattingly,
Rowlett, Graff & Hatton, 1991). Taken together, these findings suggest that Dl
receptor stimulation mediates the development of sensitization.

IV. Dopamine Agonists and Behavioral Sensitization:
In addition to using selective dopamine antagonists, researchers have also used

drugs that directly and selectively activate a particular subfamily of dopamine
receptors to study receptor mechanisms mediating the development of behavioral
sensitization. Based upon the dopamine antagonist studies discussed previously, it
would be predicted that the repeated stimulation of dopamine D 1-type, but not D2type, receptors would result in the development of behavioral sensitization. The
results of these selective agonist studies, however, indicate that receptor involvement
in mediating the development of sensitization is more complex than initially conceived.
For example, the acute administration of the selective dopamine Dl-type receptor
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agonist, SKF 383 93, inhibits locomotor activity in rats, and this inhibition does not
change with repeated daily treatments (Mattingly, Rowlett, & Lovell, 1993). On the
surface, this finding appears inconsistent with the view that DI receptor stimulation is
responsible for sensitization. However, numerous studies have indicated that
dopamine DI and D2 receptors interact and that many dopamine-mediated behaviors
are not expressed unless both receptor subtypes are stimulated (White, 1987).
Consistent with this view, rats previously treated chronically with SKF 38393 display
cross-sensitization to the activating effect of the direct-acting Dl/D2 dopamine
receptor agonist apomorphine (Mattingly et al., 1993). Thus, consistent with the
antagonist findings, repeated stimulation of dopamine DI-type receptors does appear
to induce a sensitized response. This sensitized response, however, is only expressed
when both DI and D2 receptors are activated (Mattingly et al., 1993).
As mentioned, based upon the antagonist findings, it would be predicted that
repeated stimulation of dopamine D2-type receptors should not result in the
development of behavioral sensitization. In contrast to this prediction, numerous
studies have demonstrated that the repeated administration of the dopamine D2-type
agonist, quinpirole induces sensitization (Mattingly et al., 1993; Szechtman,
Talangbayan, & Eilam, 1993), and cross-sensitization to apomorphine (Mattingly et
al., 1993). Moreover, the D2-type agonist bromocriptine also produces sensitization
with repeated administration (Hoffman & Wise, 1992). These findings appear to be in
direct conflict with the antagonist studies discussed previously indicating that D2
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receptor stimulation is not necessary for the development of sensitization to either
apomorphine or amphetamine (Drew & Glick, 1990; Stewart & Vezina, 1989; Vezina
& Stewart, 1989). However, subsequent research indicated that the development of
sensitization the DZ-type agonists, quinpirole and bromocriptine, can be prevented
with concurrent treatments with drugs that block DI-type receptors (Mattingly et al.,
1993; Wise & Carlezon, 1994). These latter findings suggest that D2 receptor
stimulation induces sensitization indirectly through DI receptors. Together with the
antagonist findings, the selective agonist results suggest that although dopamine D2
receptor stimulation may contribute to the development of behavioral sensitization,
repeated dopamine DI receptor stimulation is both necessary and sufficient for the
induction of behavioral sensitization (Mattingly et al., 1993).

V. Dopamine Receptor Involvement in Cocaine-Induced Behavioral Sensitization:
It is generally accepted that nearly all drugs that directly or indirectly stimulate
dopamine receptors. induce behavioral sensitization with repeated stimulation (Kalivas
& Stewart, 1991; Robinson & Becker, 1986; Robinson & Berridge, 1993). This has

led many researchers to conclude that sensitization is a unitary process mediated by
common mechanisms within the dopaminergic system. The research discussed
previously with selective dopamine receptor agonists and antagonists along with work
with amphetamine and apomorphine, collectively suggests that a critical factor in the
development of sensitization to all drugs is the repeated stimulation of dopamine D 1-
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type receptors. For the most part, sensitization research with cocaine has been
consistent with this view. For example, White and colleagues have demonstrated that
repeated cocaine treatments result in a transient subsensitivity of dopamine D2
autoreceptors, and a long-lasting increase in the sensitivity of dopamine D 1 receptors

in the nucleus accumbens (Henry & White, 199l;White, 1996). These
electrophysiological findings, of course, are consistent with the conclusions drawn
from previous research with amphetamine and apomorphine (Drew & Glick, 1990;
Vezina & Stewart, 1989; Stewart & Vezina, 1989). However, recent research which
has attempted to block the development of cocaine-induced sensitization with selective
dopamine antagonists has been inconsistent with these findings. For example,
Mattingly and colleagues were unable to prevent the development of sensitization to
cocaine with the selective dopamine DI-type receptor antagonist, SCH 23390 or the
D2-type antagonist, sulpiride (Mattingly, Hart, Lim & Perkins, 1994; Mattingly,
Rowlett, Ellison & Rase, 1996). Similar findings have also been reported using mice
(Kurihara & Uchihashi, 1993). These antagonist findings suggest that, unlike other
dopamine agonists such as amphetamine and apomorphine, stimulation of dopamine
DI-type receptors is not critical to the development of sensitization to cocaine.
Moreover, these discrepant results with cocaine suggest that the development of
behavioral sensitization to dopamine agonists may not be mediated by common
neurochemical mechanisms.
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Although selective dopamine antagonists are ineffective in preventing the
development of cocaine-induced behavioral sensitization, a recent study has found that
high doses of the moderately selective dopamine D2-type antagonist, haloperidol, does
prevent the development of cocaine-induced behavioral sensitization (Mattingly et al.,
1996). This finding is perplexing because highly selective D2-type antagonists do not
block the induction of sensitization to cocaine. However, since a very high dose of
haloperidol was used, it is possible that at this dose both DI and D2-type receptors
were antagonized (Mattingly et al., 1996). If so,. then this would suggest that cocaineinduced behavioral sensitization may develop through the repeated stimulation of
either D 1 or D2-type receptors. Thus, blocking sensitization to cocaine would require
simultaneously blocking both receptor subtypes. It should be noted, however, that in
addition to blocking dopamine receptors, haloperidol is also an antagonist at serotonin
receptors and has a high affinity for sigma receptors (O'Dell et al., 1990; Quiron et al.,
1992). Consequently, the exact mechanisms responsible for haloperidol's effectiveness
in preventing cocaine-induced sensitization remain unclear.

VII. Purpose of Present Study:
As discussed above, the development of sensitization to cocaine appears to be
mediated differently from other dopamine agonists. Unlike sensitization to
amphetamine and apomorphine, which appears to be mediated exclusively by
stimulation of dopamine D 1 receptors, it appears that cocaine-induced sensitization

L
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may develop through the repeated stimulation of either dopamine receptor subtype.
The purpose of the present study, therefore, was to test this latter hypothesis by
determining whether cocaine-induced behavioral sensitization could be prevented by
selectively blocking both DI and D2 receptors concurrently. Consequently, groups of
rats were repeatedly given either cocaine or vehicle in combination with a cocktail of
the DI antagonist, SCH 23390 and the D2 antagonist, eticlopride or vehicle.
Following this chronic pretreatment phase, all rats were given a challenge injection of
cocaine alone to test for sensitization. If the development of cocaine-induced
behavioral sensitization is mediated by dopamine receptors, then the combination of
SCH 23390 and eticlopride should prevent the development of sensitization.
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CHAPTER2
METHODS

Subjects
Forty-eight male Wistar albino rats were obtained from Harlan SpragueDawley, Inc. Indianapolis, Indiana. The rats weighed between 250-300g prior to
testing. The rats were housed individually in standard wire-mesh cages in a
temperature-controlled colony room with a 12 hr light-dark cycle. All testing was
conducted during the light phase of the cycle. The rats were housed in the colony
room for at least one week prior to the beginning of the experiment. During this time,
each rat was weighed and handled for five min every other day. All rats had food and
water available ad libidum.
Apparatus
Activity measures were taken in four square Med-Associates open field test
chambers (Med-Associates model OFA-163, see Figure 1). These chambers were
approximately 41 x 41 cm., and equipped with a 16 x 16 array of infrared photocell
beams positioned 2.5 cm. above the floor and a single array of 16 photocells mounted
10 cm. above the floor. A clear cylindrical acrylic chamber was positioned inside the
outer square chamber. Output from each individual photocell array was connected to
a Gateway 2000 (PS-75) microcomputer through a Med-Associates interface, located
in an adjacent room. Using Med-Associates software, the following measures were
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recorded during each test session: distance traveled, stereotypical counts, and vertical
counts (rearings).

cm

~

I

41 cm

Figure 1. Med-Associates locomotor activity testing chambers.
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The following drugs were dissolved daily in distilled H 20: cocaine
hydrochloride, eticlopride and SCH 23390. All drugs were injected subcutaneous
(S.C.) or intraperitoneal (I.P.) in a volume of I ml/kg. All drug dosages were
calculated based upon salt weight of the drug. Control injections were given using the
same vehicle, route of administration, and volume as the corresponding drug injection.
Design & Procedure
The design of the experiment was a 2 x 2 factorial design, combining two
antagonist doses and two cocaine doses. There were 12 rats per group and all rats
were randomly assigned and counterbalanced within the 4 pretreatment groups. A
summary of the experimental design is shown below in Table I and the
counterbalancing procedure is depicted in Table 8, Appendix B.

Table I
Experimental Design
Pretreatment groups (2 X 2 Factorial Design)
Second injection (I.P.)
COCAINE
VEHICLE
First injection (S.C.)
SCH-23390/
ETICLOPRIDE

SE-C (N=12)

SE-V (N=l2)

VEHICLE

V-C (N=l2)

V-V (N=l2)

15

The experiment was divided into two phases: a pretreatment phase, and a
cocaine challenge test. During the pretreatment phase each rat was first injected S.C.
with the selective DI dopamine antagonist SCH-23390 (0.10 mg/kg) and the selective
dopamine D2 antagonist eticlopride (0.10 mg/kg) in combination or vehicle. Twentyfive min later each rat was injected I.P. with cocaine (15 mg/kg), or an equivalent
volume of vehicle. Five min after the cocaine injection, the rats were placed in the
activity chambers for 60 min and tested for locomotor activity. This pre-treatment
phase was repeated for four days.
Twenty-four hours after the pre-treatment phase, all rats were first given a
vehicle injection, S.C., and 25 min later, subsequently administered a challenge
injection of cocaine (IO mg/kg I.P.) to test for behavioral sensitization.
Data Analysis
Statistical tests included mixed-factor analyses of variance with drug treatment
conditions as between-groups factors and activity test sessions and blocks within
sessions as repeated measures. These analyses were supplemented, when appropriate,
with Newman-Keuls post hoc tests.
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CHAPTER3
RESULTS
Pretreatment Sessions- Days 1-4
Distance Traveled:
The mean distance traveled in cm for each of the four pretreatment groups for
the four 60 min pretreatment sessions is depicted in Figure 2, and the within session
activity of the four pretreatment groups on Day 1 through Day 4 is depicted in Figure
3. A mixed factor analysis of variance was performed on the mean distance traveled
data with drug treatment conditions as between-groups factors and activity test
sessions and blocks within sessions as repeated measures (see Appendix A, Table 2).
As may be seen in Figure 2, rats treated with the antagonist combination (i.e.,
Sch/Etic-Vehicle, Sch/Etic-Cocaine groups) were significantly less active than the
vehicle control rats, [antagonist effect: E(l, 44) = 200.35, 11 < .0001]. Although rats
treated with only cocaine (i.e., Vehicle-Cocaine) were significantly more active than
the vehicle control rats (i.e., Vehicle-Vehicle), cocaine did not significantly increase
the activity of rats concurrently treated with the antagonist combination [cocaine
effect: E(l, 44) = 83.43, 11 < .0001; Antagonist x Cocaine interaction: F:(1, 44) =
82.22, 11 < .0001]. That is, the antagonist pretreatment completely blocked the acute
activating effect of cocaine on each day. As shown in Figure 3, the activity of the
Vehicle-Cocaine and the Vehicle-Vehicle groups decreased across the four 15 min
blocks within each 60 min session, whereas the activity of the two antagonist groups
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remained consistently low across blocks, [block effect: E(3, 132) = 219.12, .Q < .0001;
Antagonist x Block interaction: E(3, 132) = 221.12, .Q < .0001; Cocaine x Block
interaction: E(3, 132) = 52.14, .Q < .0001; Antagonist x Cocaine x Block interaction:
E(3, 132) = 52.73, .Q < .0001]. Although the activity of rats treated with only cocaine
tended to increase across days, this increase was not significant, [Cocaine x Day
interaction: E(3, 132) = 1.67, Q > .05]. Likewise, the activity of the other groups did
not significantly change across days, as neither the day effect nor any of the
interactions including day as a factor were significant (see Appendix A, Table 2).
Stereotypic Counts:
The mean number of stereotypic counts for each of the four pretreatment
groups for the four 60 min pretreatment sessions is depicted in Figure 4, and the
within session activity of the four pretreatment groups on Day 1 through Day 4 is
depicted in Figure 5. A mixed factor analysis of variance was performed on the
stereotypic data with drug treatment conditions as between-groups factors and activity
test sessions and blocks within sessions as repeated measures (see Appendix A, Table
3).
As may be seen in Figure 4, the results for the stereotypic count data are
similar to those obtained for the distance traveled data. That is, rats treated with the
antagonist combination (i.e., Sch/Etic-Vehicle, Sch/Etic-Cocaine groups) were
significantly less active than the vehicle control rats, [antagonist effect: E(l, 44) =
489.21, .Q < .001]. Although rats treated with only cocaine (i.e., Vehicle-Cocaine)
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were significantly more active than the vehicle control rats (i.e., Vehicle-Vehicle),
cocaine did not significantly increase the activity of rats concurrently treated with the
antagonist combination [cocaine effect: l:(1, 44) = 100.89, rr < .001; Antagonist x
Cocaine interaction: E(l, 44) = 102.60, rr < .0001]. That is, the antagonist
pretreatment completely blocked the acute activating effect of cocaine on each day.
As may be seen in Figure 5, the activity of the Vehicle-Cocaine and Vehicle-Vehicle

groups decreased across the four 15 min blocks within each 60 min session, whereas
the activity of the Sch/Etic-Vehicle and Sch/Etic-Cocaine groups remained
consistently low across blocks [block effect: E(3, 132) = 168.19, rr < .0001;
Antagonist x Block interaction: E(3, 132) = 152.57, rr < .0001; Cocaine x Block
interaction: E(3, 132) = 10.32, rr < .0001; Antagonist x Cocaine x Block interaction:
E(3, 132) = 10.82, rr < .0001]. Although the activity of rats treated with only cocaine
tended to increase across days, this increase was not significant, [Cocaine x Day
interaction: E < 1.00].
Rears:
Similar mixed factor Anovas were performed on the vertical activity or rearing
data (see Appendix A, Table 4). The mean number of rears for the four pretreatment
groups over the four 60 min sessions is depicted in Figure 6.
Again, the results for the rearing data are similar to the distance traveled and
stereotypic data. As may be seen in Figure 6, That is, rats treated with the antagonist
combination (i.e., Sch/Etic-Vehicle, Sch/Etic-Cocaine groups) were significantly less
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active than the vehicle control rats, [antagonist effect: E(l, 44) = 93.81, ll. < .001].
Although rats treated with only cocaine (i.e., Vehicle-Cocaine) were significantly more
active than the vehicle control rats (i.e., Vehicle-Vehicle), cocaine did not significantly
increase the activity of rats concurrently treated with the antagonist combination
[cocaine effect: E(l, 44) = 28.93, ll. < .001; Antagonist x Cocaine interaction: E(l, 44)

= 28.62, Jl. < .0001]. That is, the antagonist pretreatment completely blocked the acute
activating effect of cocaine on each day. Figure 7 displays the rearing behavior of the
four pretreatment groups across blocks of 15 min during the four pretreatment
sessions. As shown in Figure 7, the activity of the Vehicle-Cocaine and VehicleVehicle groups decreased across the four 15 min blocks within each 60 min session,
whereas the activity of the Sch/Etic-Vehicle and Sch/Etic-Cocaine groups remained
consistently low across blocks [block effect: E(3, 132) = 138.03, ll. < .0001;
Antagonist x Block interaction: E(3, 132) = 138.69, ll. < .0001; Cocaine x Block
interaction: E(3, 132) = 14.40, Jl. < .0001; Antagonist x Cocaine x Block interaction:
E(3, 132) = 14.61, Jl. < .0001]. Although the activity of rats treated with only cocaine
tended to increase across days, this increase was not significant, [Cocaine x Day
interaction: E(3, 132) = 1.21, ll. > .05]. Likewise, the activity of the other groups did
not significantly change across days, as neither the day effect nor of the interactions
including day as a factor were significant (see Appendix A, Table 4).
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Cocaine Challenge- Day 5
Distance Traveled:
A mixed factor analysis of variance was performed on the mean distance
traveled data with drug treatment conditions as between-groups factors and blocks
within sessions as a repeated measure (see Appendix A, Table 5). The mean distance
traveled for the four pretreatment groups on the 60 min cocaine challenge test is
depicted in Figure 8 and the within session activity of the groups is presented in Figure
9. As may be seen in Figure 8, overall, rats pre-exposed to cocaine for four days
were significantly more active after the cocaine challenge injection than rats receiving
cocaine for the first time [cocaine effect: E(l, 44) = 12.15, I).= .00 I], particularly on
the first three 15 min time blocks [cf Figure 9; block effect: E(3, 132) = 199.30, P. <
.0001; Cocaine x Block interaction: E(3, 132) = 8.85,

I).<

.0001). More important,

this cocaine pretreatment effect was not affected by concurrent antagonist treatments
[Antagonist x Cocaine interaction: E < 1.00; Antagonist x Cocaine x Block interaction:
E < I. 00). In fact, rats treated with the antagonist combination were significantly
more active on the cocaine challenge test than rats pretreated with only vehicle
[antagonist effect: E(!, 44) = 14.66, I).< .001). Thus, rather than blocking the
development of behavioral sensitization to cocaine, concurrent treatment with the
antagonist combination appeared to increase subsequent behavioral sensitivity to
cocaine.
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Stereotypic Counts:
The mean stereotypic counts for the four pretreatment groups during the 60
min cocaine challenge test are shown in Figure 10 and the within session stereotypic
activity of the four pretreatment groups is displayed in Figure 11. As may be seen in
Figure 10, overall, rats pretreated for four days with the antagonist combination were
significantly more responsive to the cocaine challenge injection than, rats that preexposed to cocaine or vehicle only [antagonist effect: E(l, 44) = 16.69, !l. < .0001]. As
shown in Figure 11, however, this effect was greater on blocks 3 and 4 than on blocks
I and 2, as the vehicle pretreated groups (Vehicle-Vehicle, Vehicle-Cocaine)
stereotypy scores decreased across blocks at a greater rate than did the antagonist
pretreated groups (Sch/Etic-Vehicle, Sch/Etic-Cocaine) [block effect: E(3, 132) =
114.09, !l. < .0001; Antagonist x Block interaction: E(3, 132) = 9.89, !l. < .0001].
More important, as may be seen in Figures 10 and 11, rats treated with cocaine did
not display an increase in cocaine-induced stereotypy [cocaine effect: E < 1.00;
Cocaine x Block interaction: E < 1.00] (see Appendix A, Table 6). That is, behavioral
sensitization to cocaine did not develop using the stereotypic activity as a measure.
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Rears:
The mean number of rears for the four pretreatment groups following a
challenge injection of cocaine are shown in Figure 12, and the within session rearing
activity of the pretreatment groups is depicted in Figure 13.

As may be seen, the

antagonist pretreatment groups were significantly more responsive to the cocaine
challenge on day five than vehicle or cocaine pretreatment groups [antagonist effect:

E(l, 44) = 16.86, 12 < .001], particularly on the first three 15 min time blocks [cf.
Figure 13; block effect: E(3, 132) = 102.24, 12 < .0001; Antagonist x Block interaction:

E(3, 132) = 4.51, 12 < .01] Although cocaine pretreatment did not result in an overall
increase in rearing activity [cocaine effect: E(l,44)

= 2.63, 12 > .05], rats pre-exposed

to cocaine did display significantly greater rearing activity on the first 15 min time
block compared to the vehicle pretreated rats [Cocaine x Block interaction: E(3,132)

7.70, 12 < .0001]. Thus, similar to the results using distance traveled as a behavioral
measure, these data suggest that pretreatment with cocaine produced sensitization to
cocaine-induced rearing behavior, and this effect was not blocked by concurrent
treatment with the antagonist combination.
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CHAPTER4
DISCUSSION

I. Behavioral Sensitization to Cocaine:
Behavioral sensitization is defined as a progressive increase in behavioral
sensitivity to a drug as a result ofrepeated administration. Depending upon design,
two different methods have been used to measure the development of behavioral
sensitization. One method has been to demonstrate a progressively greater behavioral
effect of a drug with each succeeding administration. For example, numerous studies
have demonstrated that the locomotor-activating effects of the direct dopamine
agonist, apomorphine increase with each succeeding administration CD,amianopoulos &
Carey, 1993; Mattingly et al., 1988; Rowlett, Mattingly, & Bardo, 1991). An
alternative method of measuring behavioral sensitization has been to compare the
effects of a challenge injection of the drug in rats previously treated with the drug to
those receiving the drug for the first time. If sensitization develops, then animals preexposed to the drug should display a significantly greater behavioral response to the
drug than animals receiving the drug for the first time. Numerous studies using
apomorphine, cocaine, and amphetamine have demonstrated the development of
behavioral sensitization in this way (Kalivas & Stewart, 1991; Martin-Iverson &
Reimer, 1994; Robinson & Becker, 1986; Segal, 1975).
In the present study, both methods of measuring behavioral sensitization were
used with three different measures of motor behavior. Consistent with previous
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studies, rats previously treated with cocaine for four consecutive days displayed a
significantly greater behavioral reaction to the cocaine challenge injection on Day 5
than rats receiving cocaine for the first time (Mattingly et al., 1996; White, Joshi,
Koeltzow & Hu, 1998). In contrast, rats pretreated with cocaine did not display a
progressive between-session increase in activity across the four pretreatment days.
This discrepancy between the two measures of sensitization has been noted before
( e.g., Martin-Iverson & Reimer, 1994). In the case of cocaine, sensitization has been
most frequently observed after a challenge test, whereas between session increases in
cocaine-induced activity are often not observed (Hooks, Jones, Smith, Neill & Justice,
1991; Mattingly et al., 1994). One factor that may contribute to this discrepancy is the
dose of cocaine used. For example, on the challenge test, a 10 mg/kg dose of cocaine
was used, whereas in the pretreatment phase, a 15 mg/kg dose was used. It is possible
that the higher dose of cocaine produced a ceiling effect with respect to activity. That
is, at this dose, the acute activating effects of cocaine may have been too high to
observe further increases in activity. By using a lower dose on the challenge test,
differences in sensitivity may have been easier to observe. In fact, this was the
rationale for using a lower dose for the challenge test. Although a lower dose could
have been used during pretreatment to avoid a possible ceiling effect, the 15 mg/kg
dose of cocaine has been shown to be the most effective dose for inducing maximum
sensitization (Kalivas, Duffy, DuMars & Skinner, 1988).
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It should be noted that behavioral sensitization to cocaine was observed on the
challenge test for the distance traveled and rearing measures, but not for the stereotypy
measure. Although a few studies have reported sensitization to cocaine using
stereotypy (Henry & White, 1995; McCreary & Marsden, 1993), the vast majority of
cocaine-sensitization studies have used horizontal locomotion and rearing as
behavioral measures (Fontanna, Post, Weiss & Pert, 1993; Kalivas et al., 1988;
Mattingly et al., 1994; Mattingly et al., 1996). Consistent with these findings,
behavioral sensitization to apomorphine is also observed using horizontal locomotion,
but not using stereotypy as a behavioral measure (Mattingly, Gotsick & Marin, 1988).
A great deal of evidence suggests that stereotypic responses induced by dopaminergic
agonists is mediated by increased stimulation of dopamine receptors in the nigrostriatal
dopamine pathway, whereas the locomotor-activating effects of dopamine agonists are
mediated by increased stimul_ation of the mesolimbic pathway (White, 1996). Ifso,
then the current findings suggest that the development of behavioral sensitization to
cocaine is mediated by alterations in the mesolimbic dopamine pathway.

II. Antagonists Effects:
As discussed previously, it has generally been assumed that the development of
behavioral sensitization to cocaine requires the repeated intermittent stimulation of
dopamine receptors (Henry & White, 1991; Kalivas & Stewart, 1991; Robinson &
Becker, 1986; Robinson & Berridge, 1993). Consistent with this view, repeated
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cocaine treatments have been shown to result in a transient subsensitivity of dopamine
D2-type autoreceptors, and a long-lasting increase in the sensitivity of dopamine D 1type receptors (Henry & White,1991; White, 1996). These changes have been
proposed to mediate the development of behavioral sensitization to cocaine and to
occur as a result of the cocaine-induced increase in extracellular dopamine (Kalivas &
Stewart, 1991; Robinson & Becker, 1986). This hypothesis would predict, however,
that concurrent treatment with dopamine antagonists would block the development of
behavioral sensitization to cocaine. Clearly, the present results are inconsistent with
this view.
In the present experiment, rats were pretreated with a combination of the
selective DI-type antagonist, SCH 23390, and the selective D2-type antagonist,
eticlopride prior to each daily cocaine treatment. This combined treatment greatly
suppressed all indices oflocomotor activity and completely blocked the locomotoractivating effects of cocaine. Thus, there appears to be no question that this drug
cocktail effectively blocked dopamine receptors. Despite this antagonism, however,
rats pretreated with the antagonist combination and cocaine were clearly
supersensitive to the cocaine challenge injection. Thus, blocking both D 1- and D2type receptors did not block the development of sensitization to cocaine.
This finding is consistent with previous work from our laboratory, which
indicated that the selective DI- and D2-type dopamine antagonists administered alone
are ineffective in preventing the development of cocaine-induced behavioral
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sensitization (Mattingly et al., 1994; Mattingly et al., 1996). Other researchers have
also failed to prevent the development of behavioral sensitization to cocaine using
other selective dopamine antagonists with mice (Kurihara & Uchihashi, 1993).
Moreover, this antagonist combination was recently shown to be ineffective in
blocking the development of cocaine-induced behavioral sensitization in a study using
a non-associative procedure and longer withdrawal intervals (White et al., 1998).
Taken together, these findings suggest that the development of behavioral sensitization
to cocaine does not require the repeated stimulation of dopamine receptors.
Curiously, it has been reported that concurrent treatments with high doses of
the relatively non-selective dopamine antagonist, haloperidol, does block the
development of cocaine-induced behavioral sensitization using a procedure similar to
that used in the current study (Mattingly et al., 1996). Moreover, haloperidol has been
reported to block the development of sensitization to cocaine using a novel oneexposure treatment paradigm (Weiss, Post, Pert, Woodward, & Murman, 1989). As
noted earlier, since very high doses of haloperidol were used in these studies, it was
assumed that haloperidol was effective because of a combined blockade of both D land D2-type receptors (cf., Mattingly et al., 1996). However, the current results are
inconsistent with this interpretation. At present, the mechanisms mediating the
effectiveness ofhaloperidol in blocking the development of sensitization to cocaine are
unclear. Nonetheless, besides blocking dopamine receptors, haloperidol also has
antagonistic actions at serotonergic receptors and has a high affinity for sigma
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receptors (O'Dell et al., 1990; Quiron et al., 1992). Thus, these non-dopaminergic
effects of haloperidol may be involved in some way in the development of behavioral
sensitization to cocaine. Indeed, cocaine is a potent inhibitor of serotonin re-uptake
and alteration in the serotonergic neurotransmitter system have been reported
following repeated cocaine administration (Ritz, Cone & Kuhar, 1990).

III. Antagonist-Induced Sensitivity to Cocaine:
As discussed previously, selective dopamine Dl-type receptor antagonists have
been reported to block the development of sensitization to other dopamine agonists
such as apomorphine, amphetamine, bromocriptine, and quinpirole (Drew & Glick,
1990; Mattingly et al., 1991; Mattingly et al., 1993; Wise & Carlezon, 1994). Thus,
the inability ofDl-type antagonists to block cocaine-induced sensitization was
unexpected since most researchers have assumed that sensitization to these drugs
involved a common dopaminergic mechanism. Another intriguing finding of the
present study is the increased sensitivity to cocaine observed in animals that were
pretreated with only the antagonist combination (cf., Figure 8.). A similar antagonistinduced increase in subsequent sensitivity to cocaine has recently been observed
following brief repeated treatments with haloperidol, SCH 23390, sulpiride, and YM09151-2 (Kurihara & Uchihashi, 1993; Mattingly et al., 1994; White, 1998).
Moreover, repeated treatments with the mixed dopamine antagonist cis-(Z)flupentixol, has been reported to increase subsequent sensitivity to cocaine in a self-
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administration paradigm (Peltier & Emmett-Oglesby, 1994). Thus, brief treatments
with dopamine antagonists appear to enhance sensitivity to both the locomotoractivating and the rewarding effects of cocaine. These findings are surprising because
repeated dopamine antagonist treatments do not increase subsequent sensitivity to
other dopamine agonists (Mattingly et al., 1991; Stewart & Vezina, 1989; Vezina &
Stewart, 1989). Taken together, these findings also suggest that the development of
sensitization to cocaine may involve a unique neurochemical mechanism.
At present, the neurochemical mechanism mediating this antagonist-induced
increase in sensitivity to cocaine is unclear. Although changes in dopamine receptors
may be involved, antagonist-induced dopamine receptor up-regulation is usually found
only after several weeks of antagonist treatments (Creese & Chen, 1985; Hess, Albers,
Le & Creese, 1986). Moreover, as noted above, the locomotor-activating effects of
the direct dopamine agonist, apomorphine, are not enhanced after similar antagonist
treatments (Mattingly et al., 1991). Despite the lack of observable morphological
changes in dopamine receptors, some recent evidence suggests brief antagonist
treatments might produce some functional changes in dopamine receptors (White et
al., 1998). For example, after brief treatments with the selective dopamine DI-type
antagonist SCH 23390, neurons with dopamine receptors in the nucleus accumbens
display an augmented electrophysiological response to dopamine (White et al., 1998).
Although the basis for this increased responsiveness is unknown, it could play a role in
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the antagonist-induced increase in behavioral sensitivity to cocaine. Clearly, additional
research is warranted to determine the exact basis for this effect.

IV. Summary and Conclusions:
The present results clearly indicate that behavioral sensitization develops to
cocaine after brief treatments. More important, the current findings indicate that the
development of sensitization to cocaine is not prevented by concurrently blocking both
DI-type and D2-type dopamine receptors. This finding suggests that other
neurochemical systems, besides dopaminergic, may be involved in the development of
sensitization to cocaine. Since sensitization to other psychostimulant drugs such as
amphetamine and apomorphine can be prevented with concurrent treatments with
mixed and selective DI-type dopamine antagonists, the current findings suggest that
cocaine-induced behavioral sensitization may be mediated by unique neurochemical
mechanisms. Moreover, the current results indicate that brief treatments with
dopamine antagonists alone increase subsequent sensitivity to cocaine. This finding
also contrasts with sensitization studies with other dopamine agonists, and further
suggests that the mechanisms mediating cocaine-induced behavioral sensitization differ
from those of other psychostimulant drugs.
The current results may have significant implications for the treatment of drug
abuse. As noted previously, one of the main factors underlying the high relapse rate
among cocaine abusers in withdrawal is the intense and persistent craving (cf.,
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Robinson & Berridge, 1993). Like sensitization, craving is known to increase in
intensity and persistence with repeated drug exposure. Thus, drugs are needed for
treatment which will block or reverse craving, and which are not reinforcing when
administered alone. Moreover, the ideal drug will also decrease subsequent sensitivity
to cocaine. Assuming that behavioral sensitization is a valid model of craving, the
present results suggest that the use of dopamine antagonists would be an ineffective
treatment for cocaine addiction. First, these agents do not block the development of
behavioral sensitization, and therefore, according to the model, would not prevent the
further development of craving if taken concurrently with cocaine. More important,
since these drugs increase subsequent sensitivity to cocaine, repeated treatments with
these agents during withdrawal may actually increase craving in the absence of the
drug. Clearly, additional research is necessary to help define precisely the
neurochemical alterations induced by repeated cocaine exposure before the
appropriate drug treatments can be developed.
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Table 2
Summary of Analysis of Variance Performed on Mean
Distance Traveled : Pretreatment Days 1-4
Source
Between Groups
Antagonist (A)
Cocaine (C)
Axe
Error

df

MS

F

nu2

200.35***
83.43***
82.22***

.82
.65
.65

1
1
1
44

205683542
85652845
84411477
1026608

Within Groups
Day (D)
AxD
CxD
AxCxD
Error

3
3
3
3
132

354268.4
371565.9
944127.9
983614.0
564925

0.63
0.66
1.67
1.74

Block (B)
AxB
CxB
AxCxB
Error

3
3
3
3
132

21050114
21241682
5008374
5065515
96065

219.12***
221.12***
52.14***
52.73***

DxB
AxDxB
CxDxB
AxCxDxB
Error

9
9
9
9
396

118099.2
124595.9
101167.1
100432.1
67240

1.76
1.85
1.50
1.49

***g.0001

.83
.83
.54
.55
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Table 3
Summary of Analysis of Variance Performed on Mean
Stereotypic Counts: Pretreatment Days 1-4
Source
Between Groups
Antagonist (A)
Cocaine (C)
AxC
Error

df

MS

1
1
1
44

753342610
155356243
158001218
1539925

Within Groups
Day (D)
AxD
CxD
AxCxD
Error

3
3
3
3
132

1678052.1
440395.7
438940.7
774374.1
850206

Block (B)
AxB
CxB
AxCxB
Error

3
3
3
3
132

29372554
26644924
1802043
1889990
174641

DxB
AxDxB
CxDxB
AxCxDxB
Error

9
9
9
9
396

338584.5
370277.3
123611.8
149978.7
102552

***n.000!
**n.001

F

nu2

489.21 ***
100.89***
102.60***

.92
.70
.70

1.97
0.52
0.52
0.91

168.19***
152.57***
10.32***
10.82***

3.30**
3.61 **
1.21
1.46

.79
.78
.19
.20

.07
.08
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Table4
Summary of Analysis of Variance Performed on Mean
Number of Rears: Pretreatment Days 1-4
Source
Between Groups
Antagonist (A)
Cocaine (C)
AxC
Error

df

MS

F

nu2

93.81 ***
28.93***
28.62***

.68
.40
.39

1
1
1
44

787328.26
242820.75
240196.26
8392.77

Within Groups
Day (D)
AxD
CxD
AxCxD
Error

3
3
3
3
132

298.8368
246.1753
2601.1910
2726.5295
2148.44

Block (B)
AxB
CxB
AxCxB
Error

3
3
3
3
132

90489.89
90921.55
9440.20
9575.41
655.58

138.03***
138.69***
14.40***
14.61 ***

DxB
AxDxB
CxDxB
AxCxDxB
Error

9
9
9
9
396

1019.410
1032.290
1463.616
1484.857
905.59

1.13
1.14
1.62
1.64

***R,0001

0.14
0.11
1.21
1.27

.76
.76
.25
.25
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Table 5
Summary of Analysis of Variance Performed on Mean
Distance Traveled: Cocaine Challenge Day 5
Source
Between Groups
Antagonist (A)
Cocaine (C)
AxC
Error
Within Groups
Block (B)
AxB
CxB
AxCxB
Error

***n.0001
**n.001

F

nu2

18530931
15357533
65300
1264380

14.66**
12.15**
0.05

.25
.22

37232750
262863
1654038
100198
186814

199.30***
1.41
8.85***
0.54

.82

df

MS

1
1
1
44

3
3
3
3
132

.17
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Table 6
Summary of Analysis of Variance Petfonned on Mean
Stereotypic Count: Cocaine Challenge Day 5
Source
Between Groups
Antagonist (A)
Cocaine (C)
AxC
Error
Within Groups
Block (B)
AxB
CxB
AxCxB
Error
***.11.000l

F

nu2

18396061
1122867
469360
1102296

16.69***
1.02
0.43

.28

21520558
1866240
168431
118972
188628

114.09***
9.89***
0.89
0.63

.72
.18

df

MS

1
1
1
44

3
3
3
3
132
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Table 7
Summary of Analysis of Variance Performed on Mean
Number of Rears: Cocaine Challenge Day 5
Source
Between Groups
Antagonist (A)
Cocaine (C)
AxC
Error
Within Groups
Block (B)
AxB
CxB
AxCxB
Error

***u.0001
**u.00l
*u.01

df

MS

F

nu2

1
1
1
44

87680.255
13685.630
1349.380
5201.75

16.86**
2.63
0.26

.28

3
3
3
3
132

93620.96
4128.13
7051.92
904.12
915.70

102.24***
4.51 *
7.70***
0.99

.70
.09
.15
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COUNTERBALANCING
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TABLES

COUNTERBALANCING
Squad#
1
1
1
1
2
2
2
2
3
3
3
3
4
4
4
4
5
5
5
5
6
6
6
6
7
7
7
7
8
8
8
8
9
9
9
9

Subject#
1
2
3
4
5
6
7
8
9
10
11

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Pretreatment Group
Vehicle-Vehicle
Vehicle-Cocaine
SCH/Etic-Vehicle
SCHIEtic-Cocaine
SCH/Etic-Vehicle
SCHIEtic-Cocaine
Vehicle-Vehicle
Vehicle-Cocaine
Vehicle-Cocaine
Vehicle-Vehicle
SCH/Etic-Cocaine
SCH/Etic-Vehicle
SCHIEtic-Cocaine
SCH/Etic-Vehicle
Vehicle-Cocaine
Vehicle-Vehicle
Vehicle-Vehicle
Vehicle-Cocaine
SCH/Etic-Vehicle
SCH/Etic-Cocaine
SCH/Etic-Vehicle
SCH/Etic-Cocaine
Vehicle-Vehicle
Vehicle-Cocaine
Vehicle-Cocaine
Vehicle-Vehicle
SCH/Etic-Cocaine
SCH/Etic-Vehicle
SCH/Etic-Cocaine
SCH/Etic-Vehicle
Vehicle-Cocaine
Vehicle-Vehicle
Vehicle-Vehicle
Vehicle-Cocaine
SCH/Etic-Vehicle
SCHIEtic-Cocaine

Chamber#
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
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TABLE 8 (Continued)
Squad#
10
10
10
10
11
11
11
11
12
12
12
12

Subject#
37
38
39
40
41
42
43
44
45
46
47
48

Pretreatment Group
SCH/Etic-Vehicle
SCH/Etic-Cocaine
Vehicle-Vehicle
Vehicle-Cocaine
Vehicle-Cocaine
Vehicle-Vehicle
SCHIEtic-Cocaine
SCH/Etic-Vehicle
SCHIEtic-Cocaine
SCH/Etic-Vehicle
Vehicle-Cocaine
Vehicle-Vehicle

Chamber#
1
2
3
4
1
2
3
4
1
2
3
4

